• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Imaging and biopsy practices in active surveillance for low-risk prostate cancer

Video

Christopher P. Evans, MD, and J. Brantley Thrasher, MD, conclude an in-depth discussion on active surveillance in men with low-risk prostate cancer.

In the second installment of J. Brantley Thrasher, MD’s interview with Christopher P. Evans, MD, regarding active surveillance for low-risk prostate cancer, Evans discusses his imaging and biopsy regimens, how he handles PI-RADS 3 lesions, and more. Evans is professor and chair of the Department of Urologic Surgery at the University of California, Davis, School of Medicine. Thrasher is executive director of the American Board of Urology, Charlottesville, Virginia.

More videos:

Key steps in pursuing a strategy of active surveillance for very low-risk prostate cancer

What is the learning curve for HIFU for prostate cancer?

App facilitates assess of urologic chronic pelvic pain syndrome

Related Videos
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
Female doctor talking with male patient | Image Credit: © Prostock-studio - stock.adobe.com
Daniel A. Triner, MD, PhD, answers a question during a Zoom video interview
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.